Literature DB >> 47234

Neuromuscular disease in secondary hyperparathyroidism.

L E Mallette, B M Patten, W K Engel.   

Abstract

Neuromuscular function was evaluated in six patients with osteomalacia or secondary hyperparathyroidism, or both, as demonstrated by bone biopsy showing osteomalacia or increased immunoreactive parathyroid hormone, or both. Each patient had weakness, atrophy, and fatigability of proximal muscles, especially of the lower extremities. Most also showed involuntary fine movements of the tongue, hyperactive tendon reflexes with abnormal spread, and decreased vibration sensation, abnormalities similar to those observed in primary hyperparathyroidism. Every patient studies had evidence of neuropathic muscle disease, either on electromyography or muscle biopsy studies histochemically or both. Muscle biopsies showed no definite myopathic features. Treatment of the osteomalacia improved muscle strength. Patients with osteomalacia therefore have a treatable neuromuscular disease that is neuropathic in nature and resembles closely that found in primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47234     DOI: 10.7326/0003-4819-82-4-474

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

1.  Proximal muscle weakness as a result of osteomalacia associated with celiac disease: a case report.

Authors:  B Oz; O Akan; H Kocyigit; H A Gürgan
Journal:  Osteoporos Int       Date:  2015-08-27       Impact factor: 4.507

2.  Models of environmentally induced neurological disease: epidemiology and etiology of amyotrophic lateral sclerosis and parkinsonism-dementia in the Western Pacific.

Authors:  R M Garruto; R Yanagihara; D C Gajdusek
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

Review 3.  Effect of uremia and its treatment on pulmonary function.

Authors:  D J Prezant
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Reversible muscle weakness in patients with vitamin D deficiency.

Authors:  K Ziambaras; S Dagogo-Jack
Journal:  West J Med       Date:  1997-12

5.  [Parathyroid dysfunction and rheumatic manifestations].

Authors:  D P Frey
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

6.  1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion.

Authors:  W E Stumpf; S A Clark; L P O'Brien; F A Reid
Journal:  Anat Embryol (Berl)       Date:  1988

7.  Treatment of secondary hyperparathyroidism in patients with chronic renal failure by total parathyroidectomy and parathyroid autograft.

Authors:  A G Diethelm; P L Adams; T M Murad; W W Daniel; J D Whelchel; E A Rutsky; S G Rostand
Journal:  Ann Surg       Date:  1981-06       Impact factor: 12.969

8.  Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease.

Authors:  Astrid Fahrleitner; Harald Dobnig; Andrea Obernosterer; Ernst Pilger; Georg Leb; Kurt Weber; Stefan Kudlacek; Barbara M Obermayer-Pietsch
Journal:  J Gen Intern Med       Date:  2002-09       Impact factor: 5.128

9.  Thoracic radiculopathy related to collapsed thoracic vertebral bodies.

Authors:  J A Liveson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-04       Impact factor: 10.154

10.  Parathyroid ablation in dystrophic hamsters. Effects on Ca content and histology of heart, diaphragm, and rectus femoris.

Authors:  G M Palmieri; D F Nutting; S K Bhattacharya; T E Bertorini; J C Williams
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.